DAXISPHARMA: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
DAXISPHARMA
Largest movements
- Current investments +€11.9m
up €11.9m (+112.4%), from €10.6m to €22.5m
- Cash -€1.5m
down €1.5m (-90.9%), from €1.7m to €149,955
mainly Current investments (-€11.9m) and Stocks and contracts (-€766,382)
- Receivables within one year -€964,888
down €964,888 (-37.0%), from €2.6m to €1.6m
of which Other amounts receivable: -€2.6m
- Tangible fixed assets -€771,159
down €771,159 (-88.9%), from €867,681 to €96,521
of which Land and buildings: -€806,806
- Stocks and contracts +€766,382
new in 2025: €766,382
- Short-term financial debts +€9.5m
up €9.5m (+131.6%), from €7.2m to €16.7m
- Tax, wage and social debts +€368,334
up €368,334 (+26.6%), from €1.4m to €1.8m
of which Taxes: +€346,166
- Purchases and services -€1.5m
no longer reported in 2025 (was €1.5m)
- Staff costs +€225,885
up €225,885 (+3.6%), from €6.3m to €6.6m
- Gross operating margin +€213,637
up €213,637 (+3.1%), from €6.9m to €7.1m
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €15,772,007 | €25,226,104 | +€9.5m | +59.9% |
| Fixed assets | 21/28 | €867,681 | €96,521 | -€771,159 | -88.9% |
| Intangible fixed assets | 21 | €0 | - | = | |
| Tangible fixed assets | 22/27 | €867,681 | €96,521 | -€771,159 | -88.9% |
| Land and buildings | 22 | €806,806 | - | -€806,806 | |
| Plant, machinery and equipment | 23 | €15,489 | - | -€15,489 | |
| Furniture and vehicles | 24 | €45,386 | €90,763 | +€45,377 | +100.0% |
| Other tangible fixed assets | 26 | - | €5,758 | +€5,758 | |
| Current assets | 29/58 | €14,904,326 | €25,129,582 | +€10.2m | +68.6% |
| Stocks and contracts in progress | 3 | - | €766,382 | +€766,382 | |
| Stocks | 30/36 | - | €766,382 | +€766,382 | |
| Amounts receivable within one year | 40/41 | €2,608,380 | €1,643,492 | -€964,888 | -37.0% |
| Trade receivables | 40 | €291 | €1,625,160 | +€1.6m | +559008.3% |
| Other amounts receivable | 41 | €2,608,089 | €18,332 | -€2.6m | -99.3% |
| Current investments | 50/53 | €10,606,449 | €22,529,676 | +€11.9m | +112.4% |
| Cash at bank and in hand | 54/58 | €1,652,187 | €149,955 | -€1.5m | -90.9% |
| Deferred charges and accrued income | 490/1 | €37,310 | €40,077 | +€2,767 | +7.4% |
| Total equity and liabilities | 10/49 | €15,772,007 | €25,226,104 | +€9.5m | +59.9% |
| Equity | 10/15 | €6,119,762 | €5,986,158 | -€133,604 | -2.2% |
| Contributions | 10/11 | €5,610,000 | €5,610,000 | = | 0.0% |
| Capital | 10 | €5,610,000 | €5,610,000 | = | 0.0% |
| Issued capital | 100 | €5,610,000 | €5,610,000 | = | 0.0% |
| Reserves | 13 | €291,073 | €299,392 | +€8,320 | +2.9% |
| Non-distributable reserves | 130/1 | €291,073 | €299,392 | +€8,320 | +2.9% |
| Legal reserve | 130 | €291,073 | €299,392 | +€8,320 | +2.9% |
| Profit (loss) carried forward | 14 | €218,689 | €76,766 | -€141,923 | -64.9% |
| Amounts payable | 17/49 | €9,652,245 | €19,239,945 | +€9.6m | +99.3% |
| Amounts payable within one year | 42/48 | €9,652,245 | €19,239,945 | +€9.6m | +99.3% |
| Financial debts | 43 | €7,209,172 | €16,699,864 | +€9.5m | +131.6% |
| Other loans | 439 | €7,209,172 | €16,699,864 | +€9.5m | +131.6% |
| Trade debts | 44 | €225,400 | €183,618 | -€41,782 | -18.5% |
| Suppliers | 440/4 | €225,400 | €183,618 | -€41,782 | -18.5% |
| Taxes, remuneration and social security | 45 | €1,383,405 | €1,751,739 | +€368,334 | +26.6% |
| Taxes | 450/3 | €206,308 | €552,474 | +€346,166 | +167.8% |
| Remuneration and social security | 454/9 | €1,177,097 | €1,199,265 | +€22,168 | +1.9% |
| Other amounts payable | 47/48 | €834,269 | €604,725 | -€229,544 | -27.5% |
| Non-recurring operating income | 76A | - | €290 | +€290 | |
| Goods, raw materials, services and sundry goods | 60/61 | €1,472,931 | - | -€1.5m | |
| Remuneration, social security and pensions | 62 | €6,341,598 | €6,567,483 | +€225,885 | +3.6% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €109,788 | €100,721 | -€9,067 | -8.3% |
| Other operating charges | 640/8 | €159,086 | €143,901 | -€15,185 | -9.5% |
| Gross operating margin | 9900 | €6,852,756 | €7,066,393 | +€213,637 | +3.1% |
| Operating profit (loss) | 9901 | €242,284 | €254,287 | +€12,003 | +5.0% |
| Financial income | 75/76B | €402,734 | €423,810 | +€21,076 | +5.2% |
| Recurring financial income | 75 | €402,734 | €423,810 | +€21,076 | +5.2% |
| Financial charges | 65/66B | €259,025 | €326,463 | +€67,438 | +26.0% |
| Recurring financial charges | 65 | €259,025 | €326,463 | +€67,438 | +26.0% |
| Profit (loss) for the period before taxes | 9903 | €385,994 | €351,635 | -€34,359 | -8.9% |
| Income taxes | 67/77 | €181,400 | €185,239 | +€3,839 | +2.1% |
| Profit (loss) for the period | 9904 | €204,594 | €166,396 | -€38,198 | -18.7% |
| Profit (loss) for the period to be appropriated | 9905 | €204,594 | €166,396 | -€38,198 | -18.7% |
Source: filed annual accounts (NBB), fiscal years ended 30 September 2024 and 30 September 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 30 September 2026 via checked.be.